EVISTA (Raloxifene) is a medication prescribed for one or more of the following: Treat or prevent osteoporosis in women who have gone through menopause., Reduce the risk of invasive breast cancer in women who have gone through menopause and have osteoporosis., Reduce the risk of invasive breast cancer in women who have gone through menopause and are at risk of developing invasive breast cancer. EVISTA is an estrogen agonist and antagonist, meaning it activates or deactivates certain estrogen receptors based on their location in the body. EVISTA is also known as a selective estrogen receptor modulator (SERM). EVISTA agonizes estrogen receptors in the bone, causing a reduction in the normal breakdown of bone that happens during bone turnover. By decreasing the breakdown of bone, EVISTA increases bone mineral density. EVISTA helps to prevent invasive breast cancer because it blocks the actions of estrogen in certain breast tissue that may become cancerous when exposed to high levels of estrogen over time. Fact Table Formula C28H27NO4S License EU EMA, US FDA Bioavailability 2% Legal status RX Only Chemical Name Raloxifene Elimination half-life Single dose: 28 hours, Multi-dose: 33 hours Dosage (Strength) 60mg (28 or 84 tablets) Pregnancy Consult a doctor Brands Evista Protein binding Greater than 95% PubChem CID 5035 MedlinePlus a698007 ChEBI 8772 ATC code G03XC01 DrugBank DB00481 KEGG D08465 Routes of administration By mouth (tablets)